Skip to main content

Table 4 HCC1954 combination index data for neratinib and tepotinib on HGF and EGF

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Tepotinib (nM)

Neratinib (nM)

Fraction inhibited (%)

Combination index

5

5

32

0.377 (n = 2)

10

10

41

0.37 (n = 2)

20

20

55

0.264 (n = 2)

30

60

62

0.062 (n = 2)

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X